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ABSTRACT
Long-term sickness absence and incapacity benefits
(disability pension) rates have increased across
industrialised countries. Effective measures are needed
to support return to work. The recommendations of this
guidance were informed by the most appropriate
available evidence of effectiveness and cost-
effectiveness. Public health evidence was provided by
research using a variety of study designs that attempted
to determine the outcome of a particular intervention by
evaluating status before and after the intervention had
been effected, and was not limited to randomised control
trials. Where the evidence base was depleted or
underdeveloped, expert witnesses were called to give
their opinion on the best available evidence and
emerging interventions. The process enabled challenge
and contestability from stakeholder groups at different
points as the guidance was developed. Forty-five
heterogeneous studies were included in the review of
interventions to reduce long-term sickness absence and
transitions from short-term to long-term absence (mainly
covering the former and also mainly examining
musculoskeletal conditions). The analysis of evidence
was restricted to descriptive synthesis. Three general
themes emerged from an analysis of the studies that
were more likely to report positive results: early
interventions; multidisciplinary approaches; and
interventions with a workplace component. Two further
reviews were undertaken, one on interventions to reduce
the re-occurrence of sickness absence, which identified
seven studies on lower back pain, and concluded that
early intervention and direct workplace input are
important factors. The final evidence review focused on
six studies of interventions for those in receipt of
incapacity benefit. The evidence was that work-focused
interviews coupled with access to tailored support are
effective and cost-effective interventions. Practitioners
should consider the impact of interventions and
management options on work ability for patients of
working age. Work ability should be considered a key
outcome for future intervention studies.
Keywords
evidence-based medicine; guideline; sick leave; sick
leave, cost; work capacity evaluation.
INTRODUCTION
Long-term sickness absence and incapacity benefits
(disability pension) rates have increased across
industrialised countries. In 2007, 5.8% of the
Organisation for Economic Co-operation and
Development (OECD) working-age population
received such benefits.1 On average, OECD
countries spend 0.8% of gross domestic product
(GDP) on public sickness absence benefits and 1.2%
of GDP on disability pensions (such as incapacity
benefit). The probability of returning to work after
being granted a disability pension is just 2% annually
across OECD countries.1 Effective measures to
activate long-standing benefit recipients and to
prevent the flow of people from sickness absence to
disability pension are a high priority. A recent
comprehensive review of the health of Europe’s
largest employer (the NHS) has shown important
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associations between health and wellbeing, sickness
absence, and key indicators of organisational
performance. The authors emphasised the need for
effective interventions to improve the health of the
workforce to reduce absenteeism rates.2
It is within this broad international context that in
March 2009 the National Institute for Health and
Clinical Excellence (NICE) issued guidance on
managing long-term sickness absence and
incapacity for work, as part of its public health
portfolio.3 Its publication coincides with a landmark
period in welfare reform in the UK,4 as well as the
strategic review of work and health following the
publication of Dame Carol Black’s review.5 Primarily
aimed at employers and managers, NHS clinicians,
and commissioners, the guidance is also relevant
internationally.3
The guidance uses the best available evidence to
make recommendations on which interventions,
strategies, and programmes are effective and cost-
effective in terms of reducing short-term and long-
term sickness absence, as well as enhancing return
to paid work for those in receipt of incapacity benefit
(or other similar benefits). Long-term sickness
absence was defined as absence of 4 or more
weeks, and short-term as sickness absences of less
than 4 weeks.
This paper reports the background to the
production of the guidance, including a brief
summary of the methods and available evidence
used to produce the guidance. It also provides a
synthesis of the available evidence, and a discussion
of its strengths and key gaps in the existing evidence
base, alongside consideration of a number of
contextual factors relating to the recommended
interventions and activities.
Sickness absence
International comparisons of sickness absence rates
are limited in number, and vary in the methods used
to capture relevant data. This limits the validity and
reliability of international comparisons.6 However,
there is evidence of significant variations, with rates
of at least 1 day’s absence in the previous year in
European countries ranging from 6.7% to 24.0%,
with the UK rate being 11.7%.7
The quality and accuracy of data on sickness
absence in the UK is also variable.8–10 The most recent
surveys of UK employers found that UK employees in
2008 were absent for an average of 3.3% (about 7.4
working days) of the time they were due to spend
working. Sixty-nine per cent of these reported
periods of absence involved 7 days or less, 17%
involved between 8 days and 4 weeks, and 17%
lasted for 4 weeks (20 working days) or longer.11 The
2008 Confederation of British Industry survey shows
that 95% of absences last less than 20 days, but the
remaining 5% account for 40% of all lost time.12
In 2006, an estimated 175 million working days
were lost in Britain due to sickness absence.5 The
annual cost of sickness absence and worklessness is
estimated to be in excess of £100 billion, greater than
the UK annual NHS budget, with mental ill health
costing UK business around £26 billion per year.13 A
recent study of long-term sickness absence rates in
the UK over a decade highlights substantial regional
variation, with rates highest in areas with loss of
manufacturing jobs. It is also noted that most of the
reduction in overall numbers of long-term sickness
absence benefits (4% in a decade) reflects a fall in
those entering into the benefit (inflow) rather than
increases in those getting work or entering retirement
(outflow).14
The commonest causes of long-term sickness
absence among manual workers (across all sectors in
the UK) are acute medical conditions, followed by
back pain, musculoskeletal injuries, stress, and
mental health problems.
Among non-manual workers (across all sectors),
the most common causes are stress, acute medical
conditions, mental health problems (such as
depression and anxiety), musculoskeletal injuries,
and back pain.11 A survey of all sicknotes collected
from nine practices in a region of England over a year
suggests that mild to moderate mental health
problems are now commoner than musculoskeletal
causes of absence, and prolonged absence in
particular.15 This is a common change across OECD
countries.1
Sickness absence rates vary by sex, age,
occupation, sector, region, and the size of the
workplace.8,12 Individuals who are out of work for long
periods of time due to sickness, experience a drop in
income, which can result in poverty and social
exclusion.16,17 In addition, the longer someone is not
working, the less likely they are to return to work;
consequently, most claimants absent for 6 months or
more have an 80% chance of being off work for
5 years.18
Disability pension (incapacity benefits)
In the UK, people who are medically assessed as
How this fits in
Sickness absence is a growing concern, and GPs remain at the centre of
solutions to manage certification and signposting for advice and support. NICE
provides evidence reviews and recommendations on a wide range of health
related topics, but those relating to public health are less straightforward than
conventional treatment-related technology reviews. This paper summarises the
NICE guidance, the evidence underpinning it, and the limitations of this evidence.
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being incapable of work due to illness, and who have
contributed sufficient National Insurance (social
security) payments, are entitled to claim incapacity
benefit.19 Incapacity benefit is similar in remit to the
long-term sickness and disability insurance schemes
of other western countries, such as the US’s social
security disability insurance and the disability
pensions of Germany and Sweden. In the UK, as
elsewhere in Europe, rates of incapacity benefit
claims have increased rapidly from 0.5 million in
1975 to 2.6 million in 2007.20 Around 7% of the UK
working-age population claims social security
benefits on the grounds of ill health.1 This is above
the OCED average of 5.8%. Incapacity benefit claims
also account for the largest proportion of UK social
security expenditure (11% in 2005), around £8 billion
per annum, or 1.8% of GDP.1 The two principal health
conditions upon which such claims are based are
musculoskeletal disorders and, increasingly, mental
health problems, particularly anxiety and depression.
Internationally, the pattern is similar, with mental
health problems accounting for one-third of new
disability claims across OECD countries. Mental ill
health is also a more frequent diagnosis among
younger claimants.1,21
In October 2008, a new benefit, the ‘employment
support allowance’ was introduced.4 This replaces
incapacity benefit and involves a two-tier system of
benefits in which more severely ill or disabled people
considered unable to work or with limited work
capacity due to their physical or mental condition
receive a higher level of benefit with no conditionality.
However, those who are deemed ‘sick but able to
work’ only receive full benefits if they participate in
employment initiatives such as ‘Pathways to Work’.22
METHOD
NICE has clear underpinning methodological and
process principles for both clinical and public health
guidance development.3,23 The general principles for
public health are as follows. Recommendations are
informed by the most appropriate available evidence
of effectiveness and cost-effectiveness. In public
health guidance, evidence may be provided by
research using any study design that attempts to
determine the outcome of a particular intervention by
evaluating status before and after the intervention
has been effected, and is not limited to randomised
controlled trials. Where the evidence base is
depleted or underdeveloped, expert witnesses can
be called by NICE to give their opinion on the best
available evidence and emerging interventions.
Evidence from research that has evaluated the cost-
effectiveness of interventions is also sought. Cost-
effectiveness is assessed using the quality-adjusted
life year (QALY). Processes are open and
transparent, and allow challenge and contestability
from stakeholder groups at different points as the
guidance is developed. Where scientific and other
values impinge on the assessment process, these
are made explicit. And finally, all activities are, and
must be seen to be, independent of government,
industry, and other vested interests.23
The guidance development process starts when a
‘referral’ is received from the health minister. The
referral about long-term sickness was ‘to produce
guidance for primary care and employers on the
management of long-term sickness and incapacity’.
Referrals typically contain no more detail than this.
Once the referral is made, government officials and
ministers take no further part in the process until the
work is published.
The NICE technical team supports guidance
production. They draft a scope, outlining the
proposed programme of work, incorporating the key
questions to be answered by the guidance, and
describing the populations, settings, and
interventions that would be included to initiate the
process.
This is put out to external consultation with
stakeholders, responses are collated, and they are
accessible on the web. Once amended, the final
version becomes the basis for the guidance.
Gathering the evidence
Evidence is searched for and screened for topic
relevance by a review team of academic and
research contractors commissioned by NICE, and
then appraised using well-defined inclusion and
exclusion criteria3 to determine the quality of the
evidence, its appropriateness to answer the research
questions set out in the scope, and its applicability to
specific populations and settings in England.
Following this protocol, NICE commissioned
reviews of evidence on interventions, strategies,
programmes, and policies, which aim to:
• reduce the number of employees who move from
short-term to long-term sickness absence, and to
help employees on long-term sickness absence
return to work;
• reduce the number of employees who take long-
term sickness absence on a recurring basis; and
• help recipients of incapacity benefits return to
employment (paid and unpaid).
The evidence was summarised into concise
statements describing the strength of the evidence
(data quality, quantity, consistency, and applicability
to the populations of interest).3 Details of the review
team and their reports can be found in the NICE
publication.3 Where relevant effectiveness data were
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available, an economic analysis of a selected
number of interventions was produced.
A series of five expert papers was also required to
cover important themes and emerging interventions
that had not been identified by the literature searches
used to develop the evidence reviews:
• ‘expert patients’ programme;
• condition management;
• discrimination in the labour market;
• regional employability programmes; and
• evaluation of Camden GP surgery pilot.
The role of the programme development group
The assembled evidence is considered by the
programme development group (PDG; a committee
comprising professional, lay, and academic experts
appointed by NICE following public advertisement
and transparent interview procedures), who,
supported by the NICE technical team, then craft the
recommendations. They meet monthly and use an
iterative approach to formulate the
recommendations and supporting considerations.
This includes consensus on the areas on which to
build recommendations, the populations benefiting
from the recommendations (target population), and
the groups responsible for ensuring the
recommendations would be implemented.
RESULTS
Review findings
Some 45 studies were included in the review of
interventions to reduce long-term sickness absence
and transitions from short-term to long-term
absence (mainly covering the former and also mainly
examining musculoskeletal conditions). The studies
were heterogeneous and no two studies measured
the same population, intervention, or outcome. This
meant that the analysis of evidence was restricted to
descriptive synthesis.
Three general themes emerged from an analysis of
the studies:
• early interventions or studies that examine
populations with a similar, specified length of
absence were more likely to report positive results
(although this is not a consistent finding across all
such studies) than those with later interventions or
more mixed populations;
• on balance, studies of multidisciplinary
approaches included in the review were more likely
to report positive results in terms of effectiveness
and cost-effectiveness than studies of single-
modality interventions; and
• studies with a workplace component (including
vocational counselling) were also more likely to
report successful outcomes than those that did
not include such an element.
Additionally, one study24 (using a model developed
by Haldorsen et al25) found that a return-to-work
prognosis measured at the start of the intervention
was important in determining the level of intervention
required to achieve return to work for individual
participants. This suggests that efficacy is enhanced
if interventions are designed to take into account
individual differences in return-to-work prognoses.
Eleven of the papers (that is, fewer than one-
quarter) contained sufficient evidence to be included
in the cost-effectiveness analysis of interventions to
reduce long-term sickness absence. The papers
covered a range of interventions, again mainly for
musculoskeletal conditions: six were
multidisciplinary and four were exercise-based
interventions for low-back or musculoskeletal pain,
and one was a psychological-based intervention for
minor mental disorders. In each case, the
intervention was found to be cost-effective in terms
of return to work.
The separate review covering interventions to
reduce the number of employees who take long-term
sickness absence on a recurring basis included
seven effectiveness studies (three of which were
included in the cost-effectiveness analysis), and all
were concerned with lower-back pain. Again, the
review found that the interventions that were
successful in reducing the re-occurrence of long-
term sickness absence shared certain key
characteristics:
• most involved early interventions; and
• the interventions tended to involve some direct
workplace input, either through design or
assessment, or workplace adaptation and delivery.
The final review examined UK interventions
designed to help people in receipt of disability
(incapacity) benefit to return to full-time or part-time
employment. This review covered a different
population group to the other evidence reviews,
which focused on absentee employees. This last
review found little evidence that met the inclusion
criteria (six studies in all, mainly relating to the
Pathways to Work pilot programme). However, the
evidence reviewed did indicate that an intervention
involving a work-focused interview coupled with
access to tailored support to meet health or
employability needs was effective and cost-effective
at increasing the rate of return to work among
incapacity benefit recipients.
Despite the heterogeneity of the available
evidence base, some common themes emerged.
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contexts influencing how interventions operate and
their likely success. The importance of social context
to the effectiveness of interventions has recently been
shown in relation to cardiovascular risk factors;26 it is
unlikely to be less important in relation to a complex
social intervention such as return to work.
One issue in this vein, which received particular
attention in PDG discussions, was the discrepancy
between the health conditions of the UK sickness
absence and incapacity benefits population and
those studied in the international evaluations. Many of
the studies in the international evidence base related
to (male) participants with musculoskeletal
conditions, whereas moderate mental health
problems (particularly among women) are the biggest
cause of sickness absence in the UK.15 It cannot be
Successful interventions appeared more likely to
incorporate a range of perspectives but generally
included a vocational rehabilitative element, and, for
those experiencing sickness absence, early
intervention and some form of direct contact with the
workplace. The guidance is summarised using a flow
diagram (Figure 1).
DISCUSSION
NICE guidance is primarily directed at a UK audience.
Most of the research identified in the evidence
reviews was undertaken in other European countries
(particularly the Scandinavian countries), which have
different sickness absence and social security
systems, work environments, and cultural
expectations. These may be important macro
Absence from work
Certified absence from work (eg via GP) or
self-reported sickness absence
Examples: light/less-intense
interventions
• Tailored advice
• Encouragement to be 
physically active
• Specialist referral (if needed)
(Recommendation 3)
•
Usual care and 
treatment (see 
NICE guidelines —
section 7)
Health problem
Assess and record occupation type and main duties; fitness to undertake
duties; relationship between work, health, and sickness; any relevant advice
or workplace support; the need for sickness absence
No further action 
required
Initial enquiries
Triggered by employer ideally 2–6 weeks
Explore reasons for sickness absence,
barriers, and options for returning to work
and determine whether a detailed
assessment is required
(Recommendation 1)
Detailed assessment
Explore reasons for sickness absence and
barriers and options for returning to work
Identify required interventions and services
(Recommendation 2)
Coordination and delivery of agreed
interventions and services
(Recommendation 3)
Examples: intensive interventions
• Coping strategies
• Psychological therapies
• Workplace modification
• Referral to specialist services
or vocational rehabilitation
(Recommendation 3)
Case worker
appointed
(if needed)
Return to work
Figure 1. Guidance flow
diagram: pathway for
managing long-term or
recurring short-term or
long-term sickness absence.3
©
N
at
io
n
al
In
st
it
u
te
fo
r
H
ea
lt
h
an
d
C
lin
ic
al
E
xc
el
le
n
ce
,2
00
9.
British Journal of General Practice, March 2011 e123
Discussion Papers
assumed that return to work interventions that work
for one condition will also work for the other. A related
issue was the fact that the included studies often
related to very specific and homogeneous
occupational groups (for example, male Finnish
forestry workers, or female Danish nurses), and there
were few general population studies. It was therefore
not possible to determine any differences in the
effects of interventions by socioeconomic or
demographic group.
Although these contextual issues all clearly restrict
the generalisability of the studies, conversely they
also increase the international relevance of the
resulting NICE guidance, based as it is on
international best practice (applied to a UK setting). It
also shows the important role of the PDG in judging,
interpreting, and applying evidence when developing
the guidance: it is not simply a case of evidence in
and recommendations out.
The applicability of NICE guidance is also
dependent on context, and this may be particularly
problematic when guidance is developed from
evidence derived from different populations or
systems. For example, although there was clear
scientific evidence to support the role of a case
worker in making an early assessment of sickness
absence and coordinating subsequent interventions
to facilitate return to work, this is not currently routine
practice in the UK. Access to appropriate training and
adequate supervision and consultation with more
skilled professionals, as recommended by the
guidance, is likely to be patchy and inconsistent, as
many employees do not currently have access to
occupational health services, and those (usually
larger) employers who do commission occupational
health services do not necessarily choose to buy help
with health aspects of sickness-absence
management.27
However, part of the government’s response to
Dame Carol Black’s review of the health of Britain’s
working-age people5 has been to commission11 ‘Fit
for Work Service’ pilots providing case management
for job retention and rehabilitation.28 These pilots are
spread throughout England, Scotland, and Wales,
involve a variety of configurations, and will include
national evaluation. This may help to provide UK
evidence on the practical applicability of the case
worker role in the context of NICE guidance.
The evidence that the NICE public health advisory
committees have to deal with seldom fits neatly into
the orthodoxy of the evidence-based medicine
approach. The causal chains from intervention to
outcome tend to be long and complicated, and much
of the evidence deals with the relationship between
the intervention and the outcome, and says precious
little about the points in between. Many of the
variables that are used to describe the evidence are
the characteristics of group relationships rather than
the characteristics of individuals, and do not fit easily
with the idea of simple evidence accumulation and
synthesis. Furthermore, the available evidence is often
patchy and sometimes of less than ideal quality.29
Finally, the evidence reviewed for this guidance
considered interventions that were delivered in a
primary care and/or workplace setting. Although the
emphasis was on work-related interventions, the
review searches also identified some studies that
contained evidence of the effectiveness of clinical
(treatment-related) interventions delivered in the
workplace or in primary care. The PDG recognised
that many clinical interventions have outcomes that
may impact on absenteeism rates or periods but this
was not within the scope of this guidance.
Consequently, such studies were excluded if it was
not possible to disaggregate the return-to-work-
related outcomes of interest for this guidance from the
treatment-related outcomes presented in the study.
Clinical practitioners should consider the impact of
interventions and management options on work ability
(absenteeism and presenteeism) for patients of
working age. Indeed, this should be considered a key
outcome for intervention studies. In turn, this would
contribute greatly to the development of the evidence
base for this topic. The emergence of new policies,
such as the fit note and changing welfare benefit
rules,30 raise the stakes in consultations for
conversations about health and work and the
implications of prolonged absence. There is increasing
evidence that good work is good for health.18 GPs
need to be more aware of their patients’ employment
(or worklessness), and the impact of health and illness
upon this central aspect of their lives.
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